Great summary. Charmaine is clear that the FDA is fully supporting this research and allowing fast track of parallel toxicology study reduced from 12 months to 9 months also permitting higher dose. The outcome could not have been better. One more trial before commercialization.. Rerate is imminent.
Charmaine Gittleson Speaks on FDA Feedback, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.7¢ | $117.7K | 1.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 142281 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 166 | 1 |
View Market Depth
| Last trade - 14.22pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 1.30 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.0¢ | 7.7¢ | 70249 | ||
| Last updated 14.42pm 07/05/2024 ? | |||||
| PER (ASX) Chart |